Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series

[1]  J. Fernández-Piqueras,et al.  SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms , 2023, British journal of haematology.

[2]  M. Loh,et al.  A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations , 2022, Blood.

[3]  R. Zheng,et al.  Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study , 2022, The Lancet.

[4]  S. Heatley,et al.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies , 2022, Frontiers in Cell and Developmental Biology.

[5]  L. Bonaldi,et al.  Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia , 2022, Clinical case reports.

[6]  F. Rahbarizadeh,et al.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward , 2021, Frontiers in Immunology.

[7]  F. Rahbarizadeh,et al.  CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? , 2021, Stem Cell Research & Therapy.

[8]  P. Cao,et al.  Sustained remission after ruxolitinib and chimeric antigen receptor T‐cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome‐like B‐cell precursor acute lymphoblastic leukemia with novel NPHP3‐JAK2 fusion , 2021, Genes, chromosomes & cancer.

[9]  C. Blag,et al.  Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults? , 2021, Cancers.

[10]  O. Silvennoinen,et al.  Janus Kinases in Leukemia , 2021, Cancers.

[11]  J. Simkin,et al.  What Is a Cytokine Storm and Should It Matter to Me? , 2021, The Journal of the American Academy of Orthopaedic Surgeons.

[12]  R. Taplitz,et al.  Updates in infection risk and management in acute leukemia. , 2020, Hematology. American Society of Hematology. Education Program.

[13]  Sairaj Satarker,et al.  JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy , 2020, Postgraduate medicine.

[14]  L. Griškevičius,et al.  Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study , 2020, BMC Cancer.

[15]  S. Chiaretti,et al.  A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia , 2020, Expert review of hematology.

[16]  O. Silvennoinen,et al.  The regulation of JAKs in cytokine signaling and its breakdown in disease. , 2019, Cytokine.

[17]  K. Roberts.  Genetics and prognosis of ALL in children vs adults. , 2018, Hematology. American Society of Hematology. Education Program.

[18]  M. Loh,et al.  A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase , 2018, Blood.

[19]  J. Babon,et al.  The molecular details of cytokine signaling via the JAK/STAT pathway , 2018, Protein science : a publication of the Protein Society.

[20]  S. Hubbard.  Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase , 2018, Front. Endocrinol..

[21]  M. Mohsenzadegan,et al.  The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells , 2017, Cell Communication and Signaling.

[22]  C. Nickl,et al.  Integration of ruxolitinib into dose‐intensified therapy targeted against a novel JAK2 F694L mutation in B‐precursor acute lymphoblastic leukemia , 2017, Pediatric blood & cancer.

[23]  R. Wade,et al.  Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Hiddemann,et al.  Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis , 2017, Haematologica.

[25]  M. D. Den Boer,et al.  JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia , 2016, Oncotarget.

[26]  M. Relling,et al.  Infection-related complications during treatment for childhood acute lymphoblastic leukemia , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Moorman.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia , 2016, Haematologica.

[28]  Wei Li,et al.  Effects of the I682F mutation on JAK2's activity, structure and stability. , 2015, International journal of biological macromolecules.

[29]  S. Hubbard,et al.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. , 2015, Blood.

[30]  Jing Xie,et al.  Infections During Induction Therapy of Protocol CCLG-2008 in Childhood Acute Lymphoblastic Leukemia: A Single-center Experience with 256 Cases in China , 2015, Chinese medical journal.

[31]  Sen Zhang,et al.  The Specific Roles of JAK/STAT Signaling Pathway in Sepsis , 2015, Inflammation.

[32]  C. Mullighan.  The genomic landscape of acute lymphoblastic leukemia in children and young adults. , 2014, Hematology. American Society of Hematology. Education Program.

[33]  R. Wade,et al.  Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. , 2014, Blood.

[34]  L. Zeng,et al.  The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability. , 2013, International journal of biological macromolecules.

[35]  M. Loh,et al.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.

[36]  Hiu Kiu,et al.  Biology and significance of the JAK/STAT signalling pathways , 2012, Growth factors.

[37]  E. Keskin,et al.  ALL-BFM 95 Treatment in Turkish Children with Acute Lymphoblastic Leukemia—Experience of a Single Center , 2012, Pediatric hematology and oncology.

[38]  M. Asim,et al.  Death analysis of childhood acute lymphoblastic leukaemia; experience at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. , 2011, JPMA. The Journal of the Pakistan Medical Association.

[39]  F. Sigaux,et al.  PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. , 2011, Blood.

[40]  A. Quintás-Cardama,et al.  New JAK2 inhibitors for myeloproliferative neoplasms , 2011, Expert opinion on investigational drugs.

[41]  J. Renauld,et al.  Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors , 2011, Haematologica.

[42]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[43]  E. Domany,et al.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.

[44]  P. D. Dal Cin,et al.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[45]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[46]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[47]  S. Malempati,et al.  Emergency department presentation of childhood cancer. , 2009, Emergency medicine clinics of North America.

[48]  M. Kyba,et al.  A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation* , 2009, The Journal of Biological Chemistry.

[49]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[50]  J. Cools,et al.  JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines , 2009, Haematologica.

[51]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[52]  G. Escherich,et al.  Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia , 2008, Pediatric blood & cancer.

[53]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[54]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[55]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[56]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[57]  M. Loh,et al.  Outcome modeling with CRLF 2 , IKZF 1 , JAK , and minimal residual disease in pediatric acute lymphoblastic leukemia : a Children ’ s Oncology Group Study , 2012 .

[58]  E. Domany,et al.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.

[59]  M. Onciu.  Acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.

[60]  S. Constantinescu,et al.  A unique clonal JAK 2 mutation leading to constitutive signalling causes polycythaemia , 2005 .